XML 18 R8.htm IDEA: XBRL DOCUMENT
v3.26.1

FINANCIAL INSTRUMENTS | 3 Months Ended
--- | ---
Mar. 31, 2026
Investments, Debt and Equity Securities [Abstract] |
FINANCIAL INSTRUMENTS | FINANCIAL INSTRUMENTS All marketable securities were classified as available-for-sale as of March 31, 2026 and December 31, 2025. The following tables show the Company’s cash, cash equivalents, restricted cash equivalents and available-for-sale securities by significant investment category as of the dates presented:
| March 31, 2026
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Aggregate Fair Value |  | Cash and Cash Equivalents |  | Restricted Cash Equivalents |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 352,248 |  |  | $ | — |  |  | $ | — |  |  | $ | 352,248 |  |  | $ | 352,248 |  |  | $ | — |  |  |  |  |
Level 2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market instruments | 2,720,187 |  |  | — |  |  | — |  |  | 2,720,187 |  |  | 1,870,187 |  |  | 850,000 |  |  |  |  |
Total | $ | 3,072,435 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,072,435 |  |  | $ | 2,222,435 |  |  | $ | 850,000 |  |  |  |  |
| December 31, 2025
| Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Aggregate Fair Value |  | Cash and Cash Equivalents |  | Short-term Marketable Securities (1) |  | Long-term Marketable Securities (2)
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 415,760 |  |  | $ | — |  |  | $ | — |  |  | $ | 415,760 |  |  | $ | 415,760 |  |  | $ | — |  |  | $ | — |
Level 2: |  |  |  |  |  |  |  |  |  |  |  |  |
Money market instruments | 895,919 |  |  | — |  |  | — |  |  | 895,919 |  |  | 895,919 |  |  | — |  |  | — |
Corporate debt securities | 472,572 |  |  | 3,286 |  |  | (3) |  |  | 475,855 |  |  | — |  |  | 189,566 |  |  | 286,289 |
U.S. government agency securities | 206,018 |  |  | 1,197 |  |  | (1) |  |  | 207,214 |  |  | — |  |  | 59,115 |  |  | 148,099 |
Asset-backed securities | 57,687 |  |  | 420 |  |  | (4) |  |  | 58,103 |  |  | — |  |  | 249 |  |  | 57,854 |
Subtotal | 1,632,196 |  |  | 4,903 |  |  | (8) |  |  | 1,637,091 |  |  | 895,919 |  |  | 248,930 |  |  | 492,242 |
Total | $ | 2,047,956 |  |  | $ | 4,903 |  |  | $ | (8) |  |  | $ | 2,052,851 |  |  | $ | 1,311,679 |  |  | $ | 248,930 |  |  | $ | 492,242 |
(1) The Company’s short-term marketable securities as of December 31, 2025 mature in one year or less, and were liquidated in the first quarter of 2026 to fund the Amicus Therapeutics, Inc. (Amicus) acquisition that closed in April 2026. (2) The Company’s long-term marketable securities as of December 31, 2025 mature between one and five years, and were liquidated in the first quarter of 2026 to fund the Amicus acquisition that closed in April 2026. Restricted Cash Equivalents, Noncurrent Restricted cash equivalents consists of funds held in escrow and restricted in their use to finance a portion of total consideration for the acquisition of Amicus. Refer to Note 13 – Subsequent Events for additional details related to Amicus acquisition. The following table provides a reconciliation of cash, cash equivalents, and restricted cash equivalents reported on the Company’s Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows:
| March 31, 2026 |  |
Cash and cash equivalents | $ | 2,222,435 |  |  |
Restricted cash equivalents | 850,000 |  |  |
Cash, cash equivalents and restricted cash equivalents | $ | 3,072,435 |  |  |

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration